Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.

Quality in Organ Donation (QUOD) logo

The QUOD biobank is a joint programme by a consortium of UK academic transplant centres and NHSBT. The biobank is funded by NHSBT and the Medical Research Council and provides blood, urine and tissue samples from heart, lung, liver and kidney from consented organ donors for researchers with anonymised integrated medical records. The samples have been collected over several years with QUOD’s primary goal to identify biomarkers, explain mechanisms of injury and repair, and improve organ utilisation and transplantation. 

Under the terms of the partnership, Evotec will investigate at first samples from 1,000 donors of the QUOD biobank using a comprehensive multi-omics analysis (genomics, transcriptomics, proteomics, metabolomics). This data will complement Evotec’s existing patient database, generating a greater understanding of disease mechanisms across indications, i.e. cardio-vascular, kidney, and liver diseases. Investigation of diseased versus healthy human biomaterial using a multi-omics approach combined with clinical data will provide extensive knowledge, indispensable for advancement of organ transplantation, drug discovery as well as clinical and biomarker research.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are proud to enter this collaboration with the QUOD programme, which expands our strategic partnership with the University of Oxford beyond LAB282, our first-of-its kind academic BRIDGE partnership. Comprehensive molecular profiling of patient samples will re-define health and disease according to dysregulated molecular disease mechanisms. This will open new doors for intervention and corresponding patient stratification.”

Professor Rutger Ploeg, Co-ordinating Principal Investigator and Director of the QUOD programme at NDS, is delighted“Robust and sustainable partnerships with high-tech industrial partners such as Evotec will enhance knowledge, help identify better diagnostic tests as well as allow to develop targeted intervention. Increased insight will improve the quality of donor organs and may reduce progression of chronic disease which should benefit our patients.”

No financial terms of the agreement were disclosed.

Press release courtesy of Evotec SE.

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Omair Shariq wins Best Clinical Paper at the American Association of Endocrine Surgeons 2021 Annual Meeting

Dr Omair Shariq, a DPhil student and clinical research fellow in the Nuffield Department of Surgical Sciences (NDS) and Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM), has received the 2021 Best Presentation for Clinical Research award during the 41st Annual Meeting of the American Association of Endocrine Surgeons (AAES), which was held virtually on 25-27 April 2021.

Artificial intelligence tool for streamlining pathology workflow

A multidisciplinary team, comprising Andrea Chatrian, Dr Richard Colling, Professor Clare Verrill, Professor Jens Rittscher and colleagues, develops an algorithm for automated requesting of additional investigation in diagnostically uncertain prostate biopsies.

Government boost for digitisation and AI in pathology services

Oxford University Hospitals (OUH) is one of the NHS trusts that will benefit from a £13.5m national funding boost to further enhance cellular pathology services and provide faster and more accurate diagnosis of deadly diseases such as cancer.

How Oxford Medical Sciences is fighting Coronavirus

Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic.

Professor David Taggart presents results of the VEST III trial

On Friday 4 October, Professor David Taggart from the Nuffield Department of Surgical Sciences (NDS) presented the results of the VEST III trial at the 2019 European Cardio-Thoracic Surgery annual meeting in Lisbon, Portugal.

Blog posts

My virtual work experience with NDS and NDORMS

Louise Tan, a Year 12 student from Ballyclare in County Antrim, Northern Ireland, recently attended the joint NDS and NDORMS Virtual Work Experience. In this guest blog, Louise reflects on her experience.

Celebrating women of NDS

To celebrate 100 years since women were admitted as full members of the University and on the occasion of International Women's Day, a group of inspirational women in the Nuffield Department of Surgical Sciences (NDS) reflect on their journeys, their place in Medical Sciences and their vision for the next 100 years.

The life of a research nurse: supporting the Oxford COVID-19 Vaccine Trial

Research nurses in the NHS are playing a crucial role in helping to trial new coronavirus treatments and vaccines. Three NDS research nurses stepped up to help with the fight against this new disease. Here Bhumika Patel shares her experience of working on the Oxford COVID-19 Vaccine Trial.

Why I became a Peer Supporter

The Peer Support Programme was developed in recognition of the essential role students play in supporting and encouraging one another on a day-to-day basis throughout their time at university. NDS’ own Helen Stark discusses her experience of becoming a Peer Supporter.

Racism under the microscope

As Black History Month gets underway in the UK, NDS Athena SWAN Coordinator Emily Hotine puts racism under the microscope.